Genentech opens new $250M biologics manufacturing site in South San Francisco
While Genentech and Roche have been on the hunt for cancer therapies, they’ve also been investing in new construction.
The company announced on Tuesday that it has opened the doors to its new $250 million manufacturing site for small-batch biologics in South San Francisco.
The site, called the “Clinical Supply Center,” will eventually make Genentech’s experimental drugs, the Roche subsidiary tells Endpoints News via email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.